Dr. Akbar Niazi Teaching Hospital (ANTH) has been granted a license by the Drug Regulatory Authority of Pakistan (DRAP) to serve as a Clinical Trial Site for phase 3 and 4 clinical trials. DRAP’s CEO Asim Rauf presented the license to Yasir Khan Niazi, the CEO of ANTH.

ANTH has met all of DRAP’s stringent criteria, making us fully equipped to start clinical trials to provide essential data on the safety and efficacy of new medical interventions, ultimately improving the healthcare delivery.

“Our commitment to research and advancement of modern healthcare solutions for superior patient outcomes has been the propelling force behind the attainment of this milestone of operating as a DRAP-approved Clinical Trial Site”

– CEO ANTH/IMDC Yasir Khan Niazi